Blueprint Medicines (BPMC) PT Lowered to $105 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $92.26 -0.03%
Rating Summary:
18 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
18 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $105.00 (from $112.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Boston Scientific (BSX) PT Raised to $83 at Stifel
- Bunge (BG) PT Raised to $122 at Citi
- Prudential Financial (PRU) PT Raised to $116 at Evercore ISI
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
